Annovis Bio Inc. (NYSE: ANVS), a company focused on developing treatments for neurodegenerative diseases, has announced a significant expansion of its intellectual property rights. The company now holds comprehensive patent coverage for both the original and a new crystalline form of buntanetap, a promising therapeutic agent. This patent protection extends through 2046, covering the composition of matter, mechanism of action, and use in multiple indications, marking a pivotal step in the drug's development and commercialization.
The new crystalline form of buntanetap has demonstrated improved stability, with bioequivalence confirmed in both animal and human studies. These findings were recently presented at the 2025 Alzheimer’s Association International Conference, highlighting the potential of buntanetap to address critical unmet needs in neurodegenerative diseases such as Alzheimer's Disease (AD) and Parkinson's Disease (PD). The enhanced stability of the drug could lead to more effective and reliable treatments for patients suffering from these debilitating conditions.
This development is particularly significant given the growing global burden of neurodegenerative diseases. With an aging population, the prevalence of AD and PD is expected to rise, underscoring the urgent need for innovative therapies. Annovis Bio's advancement in securing patent coverage for buntanetap not only strengthens its position in the biopharmaceutical industry but also offers hope for millions of patients and their families. For more details on the patent coverage and the implications for neurodegenerative disease treatment, visit https://ibn.fm/gtiNb.
The company's commitment to addressing neurodegeneration is evident in its strategic focus on developing therapies that improve patient outcomes and quality of life. The expansion of the patent portfolio for buntanetap is a testament to Annovis Bio's dedication to innovation and its potential to make a meaningful impact in the field of neurodegenerative diseases. As the company continues to advance its clinical programs, the healthcare community eagerly anticipates further developments in the quest to combat these challenging conditions.
